Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 13/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrouridine SCHEMBL127270 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL171865 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL172272 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL11761038 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL11759489 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| Tetrahydrouridine SCHEMBL14133787 | 1.00 | CDA (0.66) | CDAMAPTSLC28A1SLC28A2SLC29A1 | |
| SCHEMBL10069547 | 0.87 | CDA (0.59) | CDAMAPT | |
| SCHEMBL12338486 | 0.87 | CDA (0.55) | CDAMAPT | |
| SCHEMBL12338454 | 0.87 | CDA (0.59) | CDAMAPT | |
| SCHEMBL10069752 | 0.87 | CDA (0.59) | CDAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125595-A1 | GEMCITABINE ANTI-CANCER DERIVATIVE, ANTI-CANCER PHARMACEUTICAL USE AND PREPARATION METHOD THEREFOR | 深圳艾欣达伟医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| US-20210077492-A1 | METHODS AND COMPOSITIONS OF TREATING PANCREATIC CANCER | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-03-18 | — | — | US | disclosed |
| EP-2416780-B1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2416781-B1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2416780-B1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-2416781-B1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | OTSUKA PHARMA CO LTD (JP) | 2017-03-08 | — | — | EP | disclosed |
| US-9567363-B2 | Certain compounds, compositions and methods | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-02-14 | — | — | US | disclosed |
| EP-2417146-B1 | (2'-DEOXY-RIBOFURANOSYL)-1,3,4,7-TETRAHYDRO-(1,3)DIAZEPIN-2-ONE DERIVATIVES FOR TREATING CANCER | OTSUKA PHARMA CO LTD (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9040501-B2 | Compositions and methods for treating cancer | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279967-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | EISAI INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010118006-A1 | (2 ' -DEOXY-RIBOFURANOSYL) -1,3,4, 7-TETRAHYDRO- (1,3) IAZEPIN-2-0NE DERIVATIVES FOR TREATING CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118010-A1 | COMBINATION OF DECITABINE WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118013-A1 | COMBINATION OF CYTIDINE-BASED ANTINEOPLASTIC DRUGS WITH CYTIDINE DEAMINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF CANCER | EISAI INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-4172889-A | ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-10-30 | — | — | US | disclosed |
| US-4118484-A | ANTIINFLAMMATORY AGENT | THE UPJOHN COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4017606-A | CYTOSINE ARABINOSIDE AND HYDROGENATED PYRIMIDINE NUCLEOSIDES | THE UPJOHN COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279977-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | RNASE1, UNG, HCCS | CDA 537/4885MAPT 4204/4885SLC28A1 3363/4885 |
| US-20100279967-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNG, DUT, DCTD | CDA 49/4885MAPT 4434/4885SLC28A1 1227/4885 |
| US-20150210730-A1 | CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS | DUT, TYMP, DPYD | CDA 134/4885MAPT 1627/4885SLC28A1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.